*This content was translated by AI.
Panacel BioTech and Panacela, a stem cell-based beauty company, announced on the 27th that they signed a memorandum of understanding (MOU) for cooperation across exosome products and related businesses at Panacel BioTech headquarters in Jung-gu, Incheon.
This agreement aims to combine the expertise and business capabilities of both companies to jointly research and develop 'Exosome' related products and expand the market.
The main contents of the agreement include ▲ product planning and R&D cooperation using exosome raw materials ▲ technical and business consultations for technological advancement and quality improvement ▲ entry into domestic and international markets and joint establishment of brand strategies.
Panacel BioTech is a technology-oriented company that has officially registered Human Umbilical Wharton's Jelly Mesenchymal Stem Cell Conditional Media Extract developed by its own researchers in the International Cosmetics Composition (INCI).
The Ministry of Food and Drug Safety has established a position in the field of cell immunotherapy and stem cell application technology through obtaining permission for cell processing facilities (2021) and designation of an advanced regenerative medical practice institution (2024) by Midas Clinic, a cooperative medical institution.
"We have confirmed new possibilities for the development of functional cosmetics raw materials through stem cell culture technology that has been accumulated so far," said Panacel BioTech's Seungho Choi CEO. "We will continue to develop technologies that improve human health and quality of life with top priority on research ethics and safety, while working closely with Panacela to speed up the development of high-functioning exosome cosmetics."
Kim Mi-joo, CEO of Panacella Co., Ltd., established a new corporation through an agreement with Panacel Bio-Tech based on the management know-how of Haeum International, which operates a beauty brand specializing in golf and outdoor.
Panacella plans to introduce a next-generation stem cell beauty brand by incorporating a trendy brand strategy with biotechnology.
"We are delighted to be with Panacel BioTec, which has unique stem cell technology," said Kim Mi-joo, CEO of Panacela. "We will provide innovative skin science solutions to domestic and foreign consumers by establishing a premium exosome beauty lineup differentiated from the existing market based on proven biomaterials."
With the signing of this MOU, the two companies plan to immediately start developing new products that maximize the efficacy of exosome raw materials, and plan to build a mid- to long-term joint development model to enter the global market in the future.
<© STARNEWS. All rights reserved. No reproduction or redistribution allowed.>
*This content was translated by AI.
